Combination Product Sponsors Should Consider Traditional Pathways Before Asking For Meeting, US FDA Says

In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.